Summary Several oncogenes and tumour-suppressor genes have been identified that may have an important role in the development of human breast carcinoma. Furthermore, some of these gene alterations may be linked to the development of invasion and subsequent metastasis. Alterations in the expression of ras p21, p53 and c-erbB-2 have all been linked to tumours with rapid cellular proliferation. but the evidence that they are of prognostic importance in patients with breast cancer is conflicting. This study explores the relationship between expression of these oncoproteins and clinical outcome in 92 patients with either locally advanced or metastatic breast cancer treated with prinmary endocrine therapy. Specimens of the primary carcinoma were available for analysis of hormone receptor, Ki67 labelling index, epidermal growth factor receptor (EGFR), c-erbB-2, p53 and ras p21. Clinical response was measured according to UICC criteria after 6 months of treatment and all patients were followed for time to progression and overall survival. As shown previously, oestrogen receptor (ER) negativity, high Ki67 labelling index and EGFR overexpression were associated with a shorter time to progression and overall survival. However, no statistically significant relationship existed between expression of ras p21, p53 or c-erbB-2 and response to treatment, time to progression or overall survival. We conclude that staining for these three oncoproteins has no role in therapeutic decision-making in patients with advanced breast cancer. The negative finding implies that while abnormal expression of these genes may have an important role in the development of breast cancer, the variations in growth characteristics of advanced breast cancer may be influenced by other factors.
The development of invasive breast carcinoma involves a multistep process which has been associated with the altered expression of several oncogenes and tumour-suppressor genes (Ernberg, 1990) . Although present research suggests that these abnormalities are not the primary genetic lesions, they may be important factors in progression to invasion and metastasis (Hall et al., 1989) . Attempts to relate the altered expression of genes such as c-erbB-2, p53 and ras p21 to the clinical outcome of patients with stage I and II invasive breast cancer has produced conflicting results (Slamon et al., 1987; Ali et al., 1988; Spandidos et al., 1989) . There has been comparatively little work on the application of oncoprotein immunostaining to patients with advanced breast cancer.
Mutation of the ras family genes is a rare event in breast carcinogenesis. However, overexpression of the ras family genes has been reported to occur frequently in human breast cancer, 55-63% of clinical stage I and II tumours Spandidos et al., 1989) . Overexpression of ras p21 protein is thought to arise from an alteration in the control of expression of the normal gene sequence rather than point mutation or amplification . Overexpression of the ras family genes may represent an additional mechanism of activation -apart from the mutations -for these genes (Spandidos and Agnantis 1984; Watson et al., 1990) . The member of the ras genes which is particularly overexpressed in breast tissue is unknown, since the antibodies used to study expression of ras proteins cannot discriminate between the three members of the ras family. A recent report indicates that N-ras may play a significant role in the development of breast tumours in rats (Mangues et al., 1994) . The al., 1986) , but this has not been confirmed by more recent studies (Spandidos et al., 1989) .
p53 is a tumour-suppressor gene. Human p53 gene protein is a nuclear phosphoprotein which is normally expressed at very low levels in almost all human cells, in which it serves to regulate cell growth and division. Alteration in the p53 gene is the most common genetic change found in human malignancies (Hollstein et al., 1991) . However overexpression of p53 does not in itself signify malignant transformation as overexpression has also been reported in a variety of premalignant lesions Bennett et al., 1992; Pignatelli et al., 1992) .
Wild-type p53 protein has a short half-life. There are a number of mutant forms of p53 protein, the majority of which stabilise the protein, making it more easily detected imunocytochemically. It has also been reported that there are situations where cells can produce unusual amounts of normal p53 protein (e.g. response to DNA damage from a variety of causes). This can be detected immunocytochemically (Hall et al., 1993; Rasbridge et al., 1993) . Care must be taken over the selection of material for immunohistochemicil studies of p53 since it has been reported that the expression of p53 protein is influenced significantly by the method of fixation used (Fisher et al., 1994) .
Positive immunostaining for p53 is seen in 27-54% of infiltrating and in situ human breast carcinomas, but is infrequently found in atypical hyperplasia, indicating that it may be significant in the early stages of breast carcinogenesis (Bartek et al., 1990; Horak et al., 1991; Poller et al., 1992 Human c-erbB-2 encodes for a receptor-like transmembrane glycoprotein, p185, which has tyrosine protein kinase activity and shares homology with the EGFR. Amplification of the c-erbB-2 gene has been observed in 20-35% of primary breast cancers (Spandidos et al., 1989; Zhou et al., 1989) . Initial studies suggested that amplification of the gene was an indicator of poor prognosis in patients with positive lymph nodes and high tumour grade (Slamon et al., 1987; Wright et al., 1989) . Overexpression of c-erbB-2 protein in the primary tumours of patients with positive lymph nodes has been confirmed in a number of studies to be a marker of poor prognosis Lovelin et al., 1991; O'Reilly et al., 1991; Gullick et al., 1991; Gusterson et al., 1992) . C-erbB-2 has also been reported to be a marker of poor prognosis in breast cancer patients with negative lymph nodes (Gullick et al., 1991; Wmstanley et al., 1991) , although in other studies the difference did not reach statistical significanc (Lovekin et al., 1991; O'Reilly et al., 1991; Gusterson et al., 1992 
Resels
Twuour biology In 41 (44.6%) of patients the index lesion was the primary breast tumour itself. The majority of patients had ductal carcinoma of no specific type (57.6%) and 20.6% had lobular carcinoma. Vascular invasion was definitely seen in 28.3% of patients. The majority of primary carcnomas were either grade 2 (42.4%) or grade 3 (54.3%).
Fify-five patients (59.8%) were ER positive while PR positivity was seen in 41.3% of patients. A total of 85.9% of tumours were Ki67 positive and 60.9% were EGFR positive. The tumours of 66 patients (71.8%) stained positive for ras p21. Only 24 patients (26.1%) had tumours which stained positive for c-erbB-2. Overall, 39 patients (58%) had tumours which stained positive for p53.
Response to hormonal therapy First-line hormonal therapy was tamoxifen in 64 patients (69.6%), Zoladex in six (6.5%), Zoladex plus tamoxifen in 19 (20.7%) and megesterol acetate in three (3.3%). Asessment by UICC criteria at 6 months showed complete response was seen in 11 (12%), partial in eight (8.7%) and static disease in Table I illustrates these relationships. There were 36 responders and 56 progressors at the 6 month assessment. The group of responders was significantly older and more likely to be post-menopausal than the progressors (mean age 60 vs 52; P = 0.002). In addition, a clinical response was more likely to be observed in locally advanced tumours than in patients whose index lesion was a distant metastatic site. There were significntly more grade 3 carcinomas in the progressors (P = 0.005), but lymphovascular invasion was not a predictor of progression.
As expected, ER negativity, PR negativity, a high Ki67 labelling index and positive EGFR staining all correlated with progression of disease on hormonal therapy. Total p53, ras p21 and c-erbB-2 staining did not correlate significantly with response to hormonal therapy. When the complete, partil and static diease was considered separately, there was no significant correlation with either the degree of ras p21 staining (P = 0.84) or with total p53 expression (P = 0.52). Time to progression (months) Relationship between clinicopathological variables and ras p21 expression Of the 92 patients, 66 (71.8%) were positive for staining for the ras p21 product. There was no significant relationship between tumour grade, ER status, PR status, Ki67, EGFR or c-erbB-2. There was a significant relationship between both the intensity of p53 staining (P = 0.006) and the per cent staining (P = 0.01), but this significance showed only a trend when the p53 product was calculated and compared with ras p21 staining (P= 0.06).
Relationship between clinicopathological variables andp53 expression
Of the 92 patients, 53 (57.6%) were positive for p53. There was a trend for p53-positive tumours to be high grade (P = 0.08), have lymphovascular invasion (P = 0.05) and be ER positive (P = 0.06) and to stain ras p21 positive (P = 0.06). However, there was no relationship demonstrated for Ki67, EGFR or c-erbB-2.
Relationship between clinicopathological variables and c-erbB-2 expression There was no correlation between c-erbB-2 and ras p21 status, p53 status or response to endocrine therapy. m, p53 S c-wI B.2 din.i mac r SG Aie eta negativity, Ki67 positivity and EGFR positivity were highly significnt for both a shorter time to progression and a poor overall survival (P<0.001). However, the staining of the orginal primary tumour for c-erbB-2, p53 and ras p21 did not correlate significantly with time to progression and overall survival. All relevant factors were examined for their influence on time to progression and overall survival using the Cox regression model. ER status (P<0.001), Ki67 (P = 0.006) and EGFR (P = 0.004) were the only factors found to be statistically significant independent predictors of time to progression. For overall survival, only ER status (P = 0.008) and Ki67 labelling index (P =0.003) were independent covariates.
The aim of the study was an attempt to identify one or more oncoproteins whose expression may serve as a guide to therapy as well as a prognostic indicator in advanced breast cancer. Examination of ras p21, p53 and c-erbB-2 showed no correlation with either clinical response, time to progression or overall survival from the date on which hormone treatment was started.
The validity of the series is confirmed by the observation that the clinical outcome variables were highly related to ER status, Ki67 and EGF receptor status. In primary breast carcinomas ER status is a measure of endocrine responsiveness (Hawkins et al., 1987; Low et al., 1992) while Ki67 and EGFRs are related to the proliferative rate of the primary tumour (Sainsbury et al., 1987; Locker et al., 1992) . Our data imply that the tumour retains its same biological characteristics in the locally advanced and metastatic phases.
The finding that there was no significant correlation between ras p21 expression and either tumour histology or the other immunohistochenical parameters is of interest in light of previous research. Work by Ohuchi et al. (1986) and Going et al. (1992) indicates that ras p21 expression increases through the histological progression from normal breast epithelium to in situ cancer. There is little further inacrease in invasive cancer and metastases have a rather heterogeneous staining, implying that the expression of ras p21 is not required for maintenance of the transformed phenotype (Fromowitz et al., 1987) . There was early evidence that enhanced ras p21 expression was associated with rapidly proliferating, high-grade tumours with lymph node metastases, but others have failed to show any relationship with histological type, tumour grade, hormone receptor status, tumour diameter, lymph node status or vascular invasion (Lundy et al., 1986; Spandidos et al., 1989) . In conjunction with the present study in advanced breast cancer, there is little support for that premise that ras p21 expression is associated with aggressive tumour behaviour.
In a previous study by our group (Dati et al., 1990) and MCF-7 and ZR-75.1 (Russell and Hung, 1992) . Further studies by the first of these two groups reported that the anti-oestrogen tamoxifen inhibited cell growth and enhanced c-erbB-2 expression in ER-positive cell lines T47D and ZR75.1. Tamoxifen had no effect on cell growth or c-erbB-2 expression in the ERnegative cell line MDA.MB231 (Antoniotti et al., 1992) . The other group has shown that while oestradiol had no effect on the growth of c-erbB-2 expression of the ER-negative cell line BT474, the addition of ER to the cell line BT-474 was sufficient to allow oestradiol to repress the expression of c-erbB-2 (Russell and Hung, 1992) . It is therefore intesting that in the present study expression of c-erbB-2 by the primary tumour did not correlate with response to endocrine therapy.
c-erbB-2 expression did not correlate with patient survival. This is contrary to a previous publication looking at a similar number but different group of patients with advanced breast cancer in which we reported that c-erbB-2 expression did correlate with survival (Lovekin et al., 1991) . It is unckar from the apparently confliing resuts of our two studies whether c-erbB-2 expression does correlate with survival in patients with advanced breast cancer.
In conclusion, immunostaining of the primary tumour with monoclonal antibodies to ras p21, c-erbB-2 and p53 either separately or as a panel of stains did not in this study provide a useful predictor of response to hormonal therapy in locally advanced or metastatic breast caer. Furthermore, these parameters bore no relationship to either the time to progression or the overall survival from the time of instituting hormonal therapy. These finings, particully for c-erbB-2, do not appear to be in keeping with in vitro data suggesting c-erbB-2 expression may be hormonally regulated, at least in ER-positive breast cancer cell lines. It would be interesting to note the effect of tamoxifen on c-erbB-2 expression of tumours by sequential biopsies. This is currently the subject of ongoing studies.
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